Targeting therapeutics to an exposed and conserved binding element of the HIV-1 fusion protein.
about
HIV evolution in early infection: selection pressures, patterns of insertion and deletion, and the impact of APOBECImmunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirsA novel composite immunotoxin that suppresses rabies virus production by the infected cells.Structural and functional roles of HIV-1 gp41 pretransmembrane sequence segmentation.Conformational changes in HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion and inactivation.Selection with a peptide fusion inhibitor corresponding to the first heptad repeat of HIV-1 gp41 identifies two genetic pathways conferring cross-resistance to peptide fusion inhibitors corresponding to the first and second heptad repeats (HR1 and HHIV entry inhibitors: a new generation of antiretroviral drugs.Measuring HIV fusion mediated by envelopes from primary viral isolates.Development of Small-molecule HIV Entry Inhibitors Specifically Targeting gp120 or gp41Cell surface assembly of HIV gp41 six-helix bundles for facile, quantitative measurements of hetero-oligomeric interactions.Interactions of HIV-1 inhibitory peptide T20 with the gp41 N-HR coiled coilTopical application of entry inhibitors as "virustats" to prevent sexual transmission of HIV infection.The cytoplasmic tail slows the folding of human immunodeficiency virus type 1 Env from a late prebundle configuration into the six-helix bundle.Complex interplay of kinetic factors governs the synergistic properties of HIV-1 entry inhibitors.Identification of a Novel Inhibitor against Middle East Respiratory Syndrome Coronavirus.The C34 Peptide Fusion Inhibitor Binds to the Six-Helix Bundle Core Domain of HIV-1 gp41 by Displacement of the C-Terminal Helical Repeat Region.Kinetic dependence to HIV-1 entry inhibition.The high mannose-type glycan binding lectin actinohivin: dimerization greatly improves anti-HIV activity.
P2860
Q21559422-E5A4C875-935D-4E53-96E6-C0C9E3EFB832Q33604776-A986F929-C6D4-4285-8BE7-ACC3550B7045Q33665168-66D9B0B7-3753-437C-997F-8FE95F8D2CDDQ34183957-AD4C11D1-EA94-4322-A979-C494DC578C96Q34225654-689FD528-F3BA-46DD-AFE1-E35921E8525CQ35599288-AF18EB31-6F49-4041-B55C-1E2D14E47075Q36262437-15223E0C-AB90-45DC-B68B-D0C2BFAC99C6Q36585516-381F84AA-A680-479B-B5DA-AA42EC8F9169Q36643050-675E080A-9347-4200-8F14-1D0AE834A966Q37065151-C9946625-3CA8-41EB-BFD7-E8905CD32AD2Q37081918-0BD8A9EA-A721-49BE-ADD0-2C157022A467Q37088591-5A016E90-68EB-403A-B2A5-11325BFAE7AAQ37747105-688E7FD1-7566-4B87-AE20-BE667DA708EDQ38684463-B7092D02-7699-4B25-9A05-70B63EF45A61Q40041480-40654599-FAEA-48F0-BECD-417757C52529Q40387378-A7AF848A-0F48-45B8-98A4-3889DCB25AB6Q43627216-40F60754-31E5-45C2-9F56-F7B42FC699CCQ45147083-7D8DC987-53D9-4525-8C6B-F6BF20570A02
P2860
Targeting therapeutics to an exposed and conserved binding element of the HIV-1 fusion protein.
description
2003 nî lūn-bûn
@nan
2003 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Targeting therapeutics to an e ...... t of the HIV-1 fusion protein.
@ast
Targeting therapeutics to an e ...... t of the HIV-1 fusion protein.
@en
Targeting therapeutics to an e ...... t of the HIV-1 fusion protein.
@nl
type
label
Targeting therapeutics to an e ...... t of the HIV-1 fusion protein.
@ast
Targeting therapeutics to an e ...... t of the HIV-1 fusion protein.
@en
Targeting therapeutics to an e ...... t of the HIV-1 fusion protein.
@nl
prefLabel
Targeting therapeutics to an e ...... t of the HIV-1 fusion protein.
@ast
Targeting therapeutics to an e ...... t of the HIV-1 fusion protein.
@en
Targeting therapeutics to an e ...... t of the HIV-1 fusion protein.
@nl
P2860
P356
P1476
Targeting therapeutics to an e ...... t of the HIV-1 fusion protein.
@en
P2093
Dean H Hamer
Michael J Root
P2860
P304
P356
10.1073/PNAS.0936926100
P407
P577
2003-04-17T00:00:00Z